- Home
- CADL vs INM Comparison
CADL vs INM Comparison
Compare CADL & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CADL
- INM
- Stock Information
- Founded
- CADL 1999
- INM 1981
- Country
- CADL United States
- INM Canada
- Employees
- CADL N/A
- INM N/A
- Industry
- CADL Biotechnology: Pharmaceutical Preparations
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- CADL Health Care
- INM Health Care
- Exchange
- CADL Nasdaq
- INM Nasdaq
- Market Cap
- CADL 234.8M
- INM 3.2M
- IPO Year
- CADL 2021
- INM N/A
- Fundamental
- Price
- CADL $4.87
- INM $3.05
- Analyst Decision
- CADL Strong Buy
- INM
- Analyst Count
- CADL 5
- INM 0
- Target Price
- CADL $21.40
- INM N/A
- AVG Volume (30 Days)
- CADL 929.7K
- INM 5.8M
- Earning Date
- CADL 08-12-2025
- INM 05-12-2025
- Dividend Yield
- CADL N/A
- INM N/A
- EPS Growth
- CADL N/A
- INM N/A
- EPS
- CADL N/A
- INM N/A
- Revenue
- CADL N/A
- INM $4,920,990.00
- Revenue This Year
- CADL N/A
- INM N/A
- Revenue Next Year
- CADL N/A
- INM N/A
- P/E Ratio
- CADL N/A
- INM N/A
- Revenue Growth
- CADL N/A
- INM N/A
- 52 Week Low
- CADL $3.79
- INM $1.72
- 52 Week High
- CADL $14.60
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- CADL 43.15
- INM 51.86
- Support Level
- CADL $4.48
- INM $3.32
- Resistance Level
- CADL $5.24
- INM $5.50
- Average True Range (ATR)
- CADL 0.30
- INM 0.37
- MACD
- CADL -0.02
- INM 0.06
- Stochastic Oscillator
- CADL 28.87
- INM 24.69
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.